Amyl Therapeutics Secures $9.1 Million in Latest Series A Funding Round

Amyl Therapeutics secured $9.1 million in its latest Series A, adding another data point to the Healthcare & Life Sciences funding market.

Amyl Therapeutics Raises $9.1 million in Funding

Amyl Therapeutics raised EUR 8.25m (approx. USD 9.1m) in a Series A extension targeting Alzheimer's disease.

Investors Behind the Funding

The round was backed by undisclosed investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Amyl Therapeutics operates in Healthcare & Life Sciences. European neuro biotech is raising extensions rather than priced up-rounds, keeping programmes alive to the next data readout. Anti-amyloid approval precedent has reopened investor willingness to fund earlier-stage aggregation targets.

Strategic Use of Funds

The company is expected to use the new capital to expand its platform, support customers, and continue scaling.

Looking Ahead

Amyl Therapeutics Raises EUR 8.25M in Series A Extension Funding

Source reference: original announcement/article.